> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bristol Myers Squibb Readies Cobenfy for Landmark Schizophrenia Launch
- URL: https://bioweek.com/bristol-myers-squibb-readies-cobenfy-for-landmark-schizophrenia-launch/
- Published: 2026-08-21T14:00:00.000Z
- Updated: 2026-08-30T12:28:36.000Z
- Description: The first new pharmacological mechanism for schizophrenia in over seventy years relies on muscarinic receptor agonism rather than dopamine D2 receptor blockade.
- Author: BioWeek
- Tags: Pipeline, Markets

For more than seven decades, the pharmacological management of schizophrenia relied entirely on dopamine D2 receptor antagonism. While first- and second-generation antipsychotics reduced positive psychotic symptoms, they frequently inflicted severe motor side effects, extrapyramidal symptoms, weight gain, and sedation, while leaving negative symptoms and cognitive impairment largely unaddressed.

Bristol Myers Squibb is preparing the commercial launch of Cobenfy (xanomeline and trospium chloride), acquired through its $14 billion purchase of Karuna Therapeutics. As the first muscarinic receptor agonist approved for schizophrenia, the therapy establishes an entirely novel neurochemical approach that modulates central cholinergic signaling without blocking dopamine receptors.

In pivotal Phase 3 EMERGENT [trials](https://www.thelancet.com/?ref=bioweek.com), the oral medication demonstrated statistically significant and clinically meaningful reductions in PANSS total scores, improving both positive and negative symptoms while demonstrating a favorable metabolic and motor tolerability profile.

### The Synergistic Dual-Molecule Architecture

The therapeutic innovation of Cobenfy rests on a clever pharmacological pairing. Xanomeline is a centrally penetrant M1/M4 muscarinic receptor agonist that stimulates cortical and striatal cholinergic circuits, modulating downstream dopamine and glutamate transmission to resolve psychotic symptoms.

However, peripheral M1/M4 stimulation historically caused intolerable gastrointestinal and cholinergic side effects. Pairing xanomeline with trospium chloride—a peripherally restricted muscarinic antagonist that cannot cross the blood-brain barrier—blocks peripheral cholinergic receptors without inhibiting central therapeutic activity.

### Commercial Expectations and Pipeline Expansion

Wall Street analysts project Cobenfy could achieve peak annual sales exceeding $5 billion, establishing a cornerstone neuropsychiatry franchise for BMS. Commercial teams are educating psychiatrists and state Medicaid formulary committees on the medication's differentiated side-effect profile.

Clinical development is also expanding into Alzheimer's disease psychosis and cognitive impairment, positioning muscarinic pharmacology as a broad platform across central nervous system disorders.